- Home
- GTE vs CRDF Comparison
GTE vs CRDF Comparison
Compare GTE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- CRDF
- Stock Information
- Founded
- GTE 2003
- CRDF 1999
- Country
- GTE Canada
- CRDF United States
- Employees
- GTE N/A
- CRDF N/A
- Industry
- GTE Oil & Gas Production
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GTE Energy
- CRDF Health Care
- Exchange
- GTE Nasdaq
- CRDF Nasdaq
- Market Cap
- GTE 158.1M
- CRDF 152.3M
- IPO Year
- GTE N/A
- CRDF N/A
- Fundamental
- Price
- GTE $4.10
- CRDF $2.27
- Analyst Decision
- GTE
- CRDF Strong Buy
- Analyst Count
- GTE 0
- CRDF 5
- Target Price
- GTE N/A
- CRDF $11.10
- AVG Volume (30 Days)
- GTE 594.4K
- CRDF 728.8K
- Earning Date
- GTE 10-30-2025
- CRDF 10-29-2025
- Dividend Yield
- GTE N/A
- CRDF N/A
- EPS Growth
- GTE N/A
- CRDF N/A
- EPS
- GTE N/A
- CRDF N/A
- Revenue
- GTE $611,444,000.00
- CRDF $545,000.00
- Revenue This Year
- GTE $5.03
- CRDF N/A
- Revenue Next Year
- GTE N/A
- CRDF N/A
- P/E Ratio
- GTE N/A
- CRDF N/A
- Revenue Growth
- GTE N/A
- CRDF N/A
- 52 Week Low
- GTE $3.09
- CRDF $1.90
- 52 Week High
- GTE $8.19
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- GTE 53.28
- CRDF 50.87
- Support Level
- GTE $3.09
- CRDF $2.20
- Resistance Level
- GTE $4.20
- CRDF $2.36
- Average True Range (ATR)
- GTE 0.23
- CRDF 0.10
- MACD
- GTE 0.02
- CRDF 0.00
- Stochastic Oscillator
- GTE 90.99
- CRDF 58.91
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.